跳到正文
原文
MedPage Today·· 7 天前精选AI 评分75

新型GLP-1受体激动剂减少酒精使用障碍患者重度饮酒天数

Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder

AI 导读

一项II期临床试验(RECLAIM)显示,pemvidutide显著减少了酒精使用障碍患者每周的重度饮酒天数,42.2%的患者在24周后实现零重度饮酒天数,且安全性良好。

推荐理由

研究显示新型GLP-1受体激动剂显著减少酒精使用障碍患者的重度饮酒天数,且安全性可接受。

正文

— 42% of patients on pemvidutide achieved zero heavy drinking days by week 24

November 12, 2026 • 3 min read

The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM trial showed.

After 24 weeks of treatment, HDDs per week decreased by 4.20 days with pemvidutide versus 2.75 days with placebo (P=0.0014), reported Henry R. Kranzler, MD, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, during the American Association for the Study of Liver Diseases annual meeting in Denver.

In addition, more patients receiving the drug achieved zero HDDs by week 24 (42.2% vs 17.4% with placebo; OR 3.8, 95% CI 1.4-10.4, P=0.0066), as well as higher rates of ≥2-level WHO Risk Drinking Levels (64.4% vs 34.8%; OR 3.3, 95% CI 1.4-7.7, P=0.0049).

"In the context of alcohol use disorder -- which can be a life-threatening condition -- the positive effects are meaningful, and the adverse events are tolerable," Kranzler told MedPage Today.

Of note, patients on pemvidutide also achieved reductions in serum phosphatidylethanol (PEth) levels compared with increases in the placebo group (least-squares mean change from baseline -153.4 ng/mL vs +22.0 ng/mL, P<0.0001).

PEth is a "highly sensitive, highly specific measure of alcohol consumption that doesn't depend on self-reporting, and is objective," Kranzler said, adding that pemvidutide showed a "very robust" effect on PEth, while the placebo group showed a small increase, "which suggests that they were reporting greater reductions in drinking than they were actually experiencing."

"Even though the primary outcome was [a reduction in heavy drinking days], I'm most impressed by the PEth findings," he noted.

According to the 2024 National Survey on Drug Use and Health, 57.9 million current alcohol users ages 12 and older engaged in binge drinking in the past month, while 27.9 million had AUD in the past year. Excessive alcohol use leads to 178,000 deaths annually, with about one-third from binge drinking.

While the FDA has approved three therapies to treat AUD, only a small percentage of people with the disorder access these drugs.

Pemvidutide has balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that reduces liver fat, inflammation, and fibrosis. A previous phase IIb trial showed that pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve fibrosis without worsening of MASH.

Studies of other GLP-1 receptor agonists have shown that they reduce drinking in people with AUD, and there's also evidence that they affect the reward system in the brain, in addition to having peripheral effects in the gastrointestinal tract.

Thus, this study in AUD was a "logical next step," Kranzler said.

In RECLAIM, 100 patients with moderate-to-severe AUD were randomized to receive subcutaneous pemvidutide or placebo once weekly for 24 weeks, together with a standardized behavioral intervention.

Participants had to be engaging in heavy drinking (28 drinks per week for men, 21 for women) with at least 3 HDDs per week (≥5 drinks per day for men, ≥4 for women) over 28 days prior to screening.

Mean age was about 50, 52% were women, mean body mass index was about 32, and roughly 75% were categorized as having severe AUD. The average number of HDDs per week was 5.6 in the placebo group and 5.9 in the pemvidutide group.

Of the 100 participants randomized, 78% and 80% in the placebo and pemvidutide groups, respectively, completed treatment, while 92% and 90% completed the study.

More participants in the pemvidutide group versus the placebo group had an increase in percent days abstinent (38.9% vs 20.5%, P=0.0075) and the drug led to a higher numerical reduction in the number of drinks per drinking day (-4.9 vs -3.8), though this was not significant.

Pemvidutide also led to reductions in body weight (percent change -8.7% vs +0.4%, P<0.0001) and Fibrosis-4 scores (-0.3 vs +0.2, P=0.0301).

Overall, the most common adverse events (AEs) were mild-to-moderate gastrointestinal events (62% in the pemvidutide group and 34% in the placebo group).

Serious AEs occurred in two patients in the pemvidutide group (including a patient with hyponatremia possibly related to the drug) and one patient in the placebo group.

There were three severe AEs related to pemvidutide (including the patient with hyponatremia, one patient with migraine, and one with fatigue, night sweats, nausea, and gastroesophageal reflux disease).

Drug-related AEs leading to treatment discontinuation occurred in 10% of patients in the pemvidutide group.

来源:MedPage Today · medpagetoday.com